4/12/2024  10:00:00 PM Chg. +0.0200 Volume Bid1:59:44 AM Ask1:59:44 AM High Low
5.1000USD +0.39% 1.72 mill.
Turnover: 7.87 mill.
5.1700Bid Size: 1,400 5.2000Ask Size: 1,200 5.1100 4.9700

Business description

Aurinia Pharmaceuticals Inc. develops and commercializes therapies for diseases with unmet medical needs. Its product, LUPKYNIS, treats active lupus nephritis. Headquartered in Victoria, Canada, it collaborates with Otsuka Pharmaceutical Co., Ltd.
 

Management board & Supervisory board

CEO
Peter Greenleaf
Management board
Joe Miller, Max Donley , Sue Evans, Scott Habig, Volker Knappertz, Michael Martin , Stephen Robertson
Supervisory board
R. Hector MacKay-Dunn, Jill Leversage, Jeffrey A. Bailey, Brinda Balakrishnan, Daniel G. Billen, Dr. Robert T. Foster, Peter Greenleaf, David R.w. Jayne, Dr. Karen Smith
 

Company data

Name: Aurinia Pharmaceuticals Inc.
Address: #140, 14315 – 118 Avenue,Edmonton, AB T5L 4S6
Phone: +1-250-744-2487
Fax: +1-250-708-4345
E-mail: -
Internet: https://www.auriniapharma.com/
Industry: Healthcare
Sector: Pharmaceutical Industry
Sub sector: Pharmaceuticals
End of financial year: 12/31
Free Float: 92.79%
IPO date: -

Investor relations

Name: -
IR phone: -
IR Fax: -
IR e-mail: ir@auriniapharma.com

Main Shareholders